Literature DB >> 7887973

Particular ability of cytochromes P450 3A to form inhibitory P450-iron-metabolite complexes upon metabolic oxidation of aminodrugs.

C Bensoussan1, M Delaforge, D Mansuy.   

Abstract

The ability of 21 drugs containing an amine function to form inhibitory P450-iron-metabolite complexes absorbing around 455 nm was studied on liver microsomes from rats treated with various P450 inducers. These drugs belong to different chemical and therapeutic series and exhibit very different structures. In the case of eight compounds (diltiazem, lidocaine, imipramine, SKF 525A, fluoxetine, L-alpha-acetylmethadol, methadol and desmethyltamoxifen) whose oxidation by microsomes from rats treated with several inducers was studied, only dexamethasone (DEX)-treated rat microsomes and, to a lesser extent, phenobarbital (PB)-treated rat microsomes, were able to give significant amounts of 455 nm absorbing complexes. Ten of the 21 compounds studied gave such complexes with DEX-treated rat microsomes, while only three compounds gave complexes (in low amounts) with PB-treated rat microsomes only. For all compounds leading to complexes both with DEX- and PB-treated rat microsomes, much higher amounts of complexes were obtained with DEX-treated rat microsomes. DEX-treated rat microsomes also led to the most intense type I spectral interactions with most of the compounds studied, and very often exhibited the highest N-dealkylation activities towards the tertiary or secondary amine function of the drugs used. A few exceptions aside, there generally exists a qualitative relationship between the ability of P450 3As, induced by DEX, to bind and N-dealkylate amino compounds and their propensity to lead to 455 nm absorbing complexes. This was confirmed by in vivo experiments showing that rats treated with diltiazem, tamoxifen or imipramine accumulated large amounts of 455 nm absorbing complexes in their liver only after pretreatment with DEX and, to a lesser extent, with PB. This particular ability of P450 3As to oxidize amino drugs with formation of inhibitory P450-metabolite complexes could be of great importance for the appearance of drug interactions in man.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7887973     DOI: 10.1016/0006-2952(94)00477-4

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  14 in total

1.  CYP3A4 drug interactions: correlation of 10 in vitro probe substrates.

Authors:  K E Kenworthy; J C Bloomer; S E Clarke; J B Houston
Journal:  Br J Clin Pharmacol       Date:  1999-11       Impact factor: 4.335

2.  Diltiazem inhibits human intestinal cytochrome P450 3A (CYP3A) activity in vivo without altering the expression of intestinal mRNA or protein.

Authors:  A G Pinto; J Horlander; N Chalasani; M Hamman; A Asghar; D Kolwankar; S D Hall
Journal:  Br J Clin Pharmacol       Date:  2005-04       Impact factor: 4.335

3.  Characterization of structure and activity of garlic peroxidase (POX(1B)).

Authors:  Sarra El Ichi; Anna Miodek; Hélène Sauriat-Dorizon; Jean-Pierre Mahy; Céline Henry; Mohamed Nejib Marzouki; Hafsa Korri-Youssoufi
Journal:  J Biol Inorg Chem       Date:  2010-11-02       Impact factor: 3.358

Review 4.  Inhibition and induction of cytochrome P450 and the clinical implications.

Authors:  J H Lin; A Y Lu
Journal:  Clin Pharmacokinet       Date:  1998-11       Impact factor: 6.447

5.  Irreversible Enzyme Inhibition Kinetics and Drug-Drug Interactions.

Authors:  Michael Mohutsky; Stephen D Hall
Journal:  Methods Mol Biol       Date:  2021

6.  Sequential metabolism of secondary alkyl amines to metabolic-intermediate complexes: opposing roles for the secondary hydroxylamine and primary amine metabolites of desipramine, (s)-fluoxetine, and N-desmethyldiltiazem.

Authors:  Kelsey L Hanson; Brooke M VandenBrink; Kantipudi N Babu; Kyle E Allen; Wendel L Nelson; Kent L Kunze
Journal:  Drug Metab Dispos       Date:  2010-03-03       Impact factor: 3.922

7.  The nitrosoamphetamine metabolite is accommodated in the active site of human hemoglobin: Spectroscopy and crystal structure.

Authors:  Samantha M Powell; Leonard M Thomas; George B Richter-Addo
Journal:  J Inorg Biochem       Date:  2020-09-29       Impact factor: 4.155

8.  An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid.

Authors:  Thomas M Polasek; David J Elliot; Andrew A Somogyi; Elizabeth M J Gillam; Benjamin C Lewis; John O Miners
Journal:  Br J Clin Pharmacol       Date:  2006-05       Impact factor: 4.335

9.  Time-dependent inhibition of human drug metabolizing cytochromes P450 by tricyclic antidepressants.

Authors:  Thomas M Polasek; John O Miners
Journal:  Br J Clin Pharmacol       Date:  2007-07-27       Impact factor: 4.335

Review 10.  The role of metabolites in predicting drug-drug interactions: focus on irreversible cytochrome P450 inhibition.

Authors:  Brooke M VandenBrink; Nina Isoherranen
Journal:  Curr Opin Drug Discov Devel       Date:  2010-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.